Logo image of ALGEN.PA

GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

EPA:ALGEN - Euronext Paris - Matif - FR0004053510 - Common Stock - Currency: EUR

3.11  +0.06 (+1.97%)

Fundamental Rating

6

Overall ALGEN gets a fundamental rating of 6 out of 10. We evaluated ALGEN against 73 industry peers in the Biotechnology industry. While ALGEN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ALGEN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year ALGEN was profitable.
In the past year ALGEN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
ALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M

1.2 Ratios

With an excellent Return On Assets value of 3.96%, ALGEN belongs to the best of the industry, outperforming 80.82% of the companies in the same industry.
ALGEN has a better Return On Equity (7.06%) than 80.82% of its industry peers.
With an excellent Return On Invested Capital value of 6.13%, ALGEN belongs to the best of the industry, outperforming 84.93% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 11.99%.
The last Return On Invested Capital (6.13%) for ALGEN is above the 3 year average (5.56%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.96%
ROE 7.06%
ROIC 6.13%
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ALGEN.PA Yearly ROA, ROE, ROICALGEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

ALGEN has a Profit Margin of 5.86%. This is amongst the best in the industry. ALGEN outperforms 80.82% of its industry peers.
The Operating Margin of ALGEN (8.09%) is better than 82.19% of its industry peers.
With an excellent Gross Margin value of 92.34%, ALGEN belongs to the best of the industry, outperforming 91.78% of the companies in the same industry.
In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
Industry RankSector Rank
OM 8.09%
PM (TTM) 5.86%
GM 92.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
ALGEN.PA Yearly Profit, Operating, Gross MarginsALGEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ALGEN has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ALGEN has been increased compared to 5 years ago.
Compared to 1 year ago, ALGEN has an improved debt to assets ratio.
ALGEN.PA Yearly Shares OutstandingALGEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALGEN.PA Yearly Total Debt VS Total AssetsALGEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

An Altman-Z score of 2.51 indicates that ALGEN is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALGEN has a Altman-Z score of 2.51. This is in the better half of the industry: ALGEN outperforms 68.49% of its industry peers.
The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.
ALGEN's Debt to FCF ratio of 1.41 is amongst the best of the industry. ALGEN outperforms 94.52% of its industry peers.
ALGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ALGEN has a Debt to Equity ratio (0.26) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.41
Altman-Z 2.51
ROIC/WACC0.86
WACC7.12%
ALGEN.PA Yearly LT Debt VS Equity VS FCFALGEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

A Current Ratio of 1.92 indicates that ALGEN should not have too much problems paying its short term obligations.
ALGEN has a Current ratio (1.92) which is comparable to the rest of the industry.
ALGEN has a Quick Ratio of 1.81. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
ALGEN has a Quick ratio of 1.81. This is comparable to the rest of the industry: ALGEN outperforms 47.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.81
ALGEN.PA Yearly Current Assets VS Current LiabilitesALGEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

ALGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.41%, which is quite good.
ALGEN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.04%.
Measured over the past years, ALGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.46% on average per year.
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%

3.2 Future

The Earnings Per Share is expected to decrease by -14.50% on average over the next years. This is quite bad
Based on estimates for the next years, ALGEN will show a quite strong growth in Revenue. The Revenue will grow by 10.37% on average per year.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y-14.5%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALGEN.PA Yearly Revenue VS EstimatesALGEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
ALGEN.PA Yearly EPS VS EstimatesALGEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2023 2024 2027 0.05 0.1 0.15 0.2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 14.81, ALGEN is valued correctly.
Based on the Price/Earnings ratio, ALGEN is valued cheaply inside the industry as 86.30% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ALGEN to the average of the S&P500 Index (27.03), we can say ALGEN is valued slightly cheaper.
Industry RankSector Rank
PE 14.81
Fwd PE N/A
ALGEN.PA Price Earnings VS Forward Price EarningsALGEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

ALGEN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALGEN is cheaper than 93.15% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 97.26% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.51
EV/EBITDA 5.12
ALGEN.PA Per share dataALGEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

ALGEN has a very decent profitability rating, which may justify a higher PE ratio.
ALGEN's earnings are expected to decrease with -14.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y-14.5%

More info and screens

0

5. Dividend

5.1 Amount

ALGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENOWAY SA

EPA:ALGEN (8/5/2025, 7:00:00 PM)

3.11

+0.06 (+1.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners9.39%
Ins Owner ChangeN/A
Market Cap29.48M
Analysts86.67
Price Target6.02 (93.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 14.81
Fwd PE N/A
P/S 1.38
P/FCF 6.51
P/OCF 4.27
P/B 1.66
P/tB 2.42
EV/EBITDA 5.12
EPS(TTM)0.21
EY6.75%
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.48
FCFY15.37%
OCF(TTM)0.73
OCFY23.43%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.96%
ROE 7.06%
ROCE 7.62%
ROIC 6.13%
ROICexc 7.79%
ROICexgc 11.35%
OM 8.09%
PM (TTM) 5.86%
GM 92.34%
FCFM 21.15%
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score5
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.41
Debt/EBITDA 0.77
Cap/Depr 55.06%
Cap/Sales 11.1%
Interest Coverage 250
Cash Conversion 114.18%
Profit Quality 360.76%
Current Ratio 1.92
Quick Ratio 1.81
Altman-Z 2.51
F-Score5
WACC7.12%
ROIC/WACC0.86
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y-14.5%
EPS Next 5YN/A
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year172.73%
EBIT Next 3Y63.41%
EBIT Next 5YN/A
FCF growth 1Y308.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1010.09%
OCF growth 3YN/A
OCF growth 5YN/A